The treatment success rate for patients with extensively drug-resistant tuberculosis (XDR-TB) in Canada has displayed a concerning decline from an estimated 62% in 2024 to an anticipated 56% in 2028. This data indicates a consistent year-on-year decrease, signaling challenges in improving outcomes for XDR-TB treatment. In comparison, the treatment success rate stood at an estimated 65% in 2023. Over the forecasted period, the compound annual growth rate (CAGR) suggests a diminishing average annual success rate, which reflects systemic issues in treatment efficacy.
Future trends to watch for include advancements in drug therapies, introduction of novel treatment protocols, and potential policy changes that could impact funding and access to treatment. Monitoring these trends will be crucial for healthcare stakeholders aiming to reverse the declining success rates.
